Skip to main content

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

In brief

Pirtobrutinib shrinks lymphoma in about half of patients after prior BTK inhibitor treatment

In the phase 1/2 BRUIN study, 49% of 152 patients with relapsed mantle cell lymphoma previously treated with a covalent BTK inhibitor responded to pirtobrutinib; responses lasted a median of 21.6 months, while median time without disease progression was 5.6 months. Infections were common, including serious infections in 21%; results in the 14 patients without prior BTK inhibitor treatment are less certain.

Journal
American journal of hematology (Q1)
Published
4 November 2026
Study design
Phase 1 (first-in-human) trial
Evidence level
Level 4, Very Low (CEBM 4)
Authors
Michael L Wang, Jonathon B Cohen, Nirav N Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y Cheah, et al.
PMID
42983593
DOI
10.1002/ajh.70533

Why clinicians should know about it

  • Picked for Hematology (paper of the day, 11 November 2026): Final efficacy and safety results for relapsed mantle cell lymphoma

Abstract

Pirtobrutinib, a highly selective, non-covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL). Here, we report final results from the global Phase 1/2 BRUIN trial evaluating pirtobrutinib in patients with R/R MCL, with and without prior cBTKi exposure. Endpoints included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. BRUIN enrolled 166 patients with R/R MCL (data cutoff: 27Jan2025). In the cBTKi-exposed cohort (n = 152), median study follow-up time was 16.1 months (range, 0.5-69.6). The ORR was 49.3% (95% CI, 41.1-57.6). Median DOR was 21.6 months (95% CI, 9.2-27.2). Median PFS was 5.6 months (95% CI, 5.3-9.2; 36-month rate, 19.9%). Median OS was 23.9 months (95% CI, 17.3-51.5; 36-month rate, 43.2%). In the cBTKi-naïve cohort (n = 14), median study follow-up time was 44.5 months (range, 1.6-67.1). The ORR was 85.7% (95% CI, 57.2-98.2). Median DOR was 42.7 months (95% CI, 25.8-not estimable [NE]). Median PFS was 44.6 months (95% CI, 16.7-NE; 36-month rate, 58.7%). Median OS was NE (36-month rate, 76.2%). The most frequent any-grade treatment-emergent adverse events (TEAEs) were infections (44.0%), fatigue (31.9%), and diarrhea (22.9%); the most frequent grade ≥ 3 TEAEs were infections (21.1%) and neutropenia (15.1%). Grade ≥ 3 hemorrhage (3.0%) and any-grade atrial fibrillation/flutter (3.6%) were infrequent. With extended follow-up, pirtobrutinib continued to demonstrate efficacy and favorable safety in cBTKi-exposed and -naïve R/R MCL. Trial Registration: ClinicalTrials.gov identifier: NCT03740529.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.